UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2010

 
PHARMACYCLICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware
000-26658
94-3148201
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
995 E. Arques Avenue, Sunnyvale, California
4085-4521
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (408) 774-0330

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 5.07
Submission of Matters to a Vote of Security Holders
 
The 2010 Annual Meeting of Stockholders of Pharmacyclics, Inc. (the “Company”) was held on December 9, 2010.  The following three matters were put forth to the stockholders to be voted on: (1) the election of seven directors to serve until the Company’s next annual meeting of stockholders and until his or her successor is duly elected and qualified; (2) an amendment of the Company’s 2004 Equity Incentive Award Plan in order to increase the total number of shares of common stock authorized for issuance over the term of the 2004 Equity Incentive Award Plan by an additional 2,500,000 shares; and (3) the ratification of the selection of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm.
 
Each of the matters submitted to a vote of the Company’s stockholders at the Annual Meeting was approved by the requisite vote of the Company’s stockholders.  Set forth below is the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes as to each such matter, including a separate tabulation with respect to each nominee for director, as applicable:
 
Nominee
For
Withheld
Broker Non-votes
Robert W. Duggan
33,212,042
158,746
19,298,395
Richard A.van den Broek
33,250,958
119,830
19,298,395
Roy C. Hardiman
33,325,677
45,111
19,298,395
Minesh P. Mehta
33,251,622
119,166
19,298,395
David D. Smith
33,251,622
119,166
19,298,395
Robert F. Booth
33,322,069
48,719
19,298,395
Gwen A. Fyfe
32,812,399
558,389
19,298,395

 
Proposal
For
Against
Abstain
Broker Non-Votes
Amendment to 2004 Equity Incentive Award Plan to increase the shares authorized for issuance by 2,500,000
31,198,088
1,966,625
206,075
19,298,395
Ratification of the appointment of PricewaterhouseCoopers LLP
52,475,663
174,737
18,783
0

 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
December 10, 2010
 
 
PHARMACYCLICS, INC.
   
   
 
By:
/s/ Rainer M. Erdtmann
   
Name:
Rainer M. Erdtmann
   
Title:
Vice President, Finance & Administration and Secretary


 
2